Pancreatic Endocrine Tumor– Pipeline Review, 2019

Pancreatic endocrine tumor or pancreatic neuroendocrine tumor refers to the development of the tumors resulting from the abnormal growth of the hormone-producing or endocrine cells in the pancreas known as islet cells. Pancreatic endocrine tumor accounts for the 7% of all pancreatic tumors and can be malignant or benign and often grow slower than the exocrine tumors. Pancreatic endocrine can be either functional (hormone-producing) or non-functional (no hormone-producing).

Based on the type of the hormone produced by the pancreatic endocrine tumor, these tumors can cause a variety of symptoms such as stomach ulcers, severe diarrhea, diabetes, hypoglycemia, gallstones, and acromegaly. Some of the various types of pancreatic endocrine tumors include insulinomas, somatostatinomas, glucagonomas, VIPomas and gastrinomas. Most of the strategies for the treatment and management of the pancreatic endocrine tumors centers around a combination approach of several therapeutic measures. Treatment options include surgical removal of the tumors, chemotherapy, radiation therapy and hormone therapy.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for pancreatic endocrine tumor. For instance; CVM-1118, which is being studied by TaiRx, Inc., is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of CVM-1118 in patients with the pancreatic neuroendocrine tumor.

To know how our report can help streamline your business, Speak to Analyst

At present more than 80% of the pipeline candidates for pancreatic endocrine tumor are in the phase-1 and phase-2 stage. Majority of the studies are sponsored by universities and academic research institutes. 

Report Description

The report on ‘Pancreatic Endocrine Tumor– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Pancreatic Endocrine Tumor. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Pancreatic Endocrine Tumor.

The report on ‘Pancreatic Endocrine Tumor – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Pancreatic Endocrine Tumor
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Pancreatic Endocrine Tumor
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary